Investors & News / taxonomy / term / code General Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March Read more about Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer Read more about Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026 Read more about Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026 Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer Read more about Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026 Read more about Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026 Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025 Read more about Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025 Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November Read more about Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 Read more about Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 Exelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development Read more about Exelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September Read more about Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September Pagination Page 1 Next page ›› Subscribe to General Receive Email Alerts Sign up to receive email alerts whenever Exelixis, Inc. posts new information to the site. Just enter your email address and click Submit. Required fields denoted by an asterisk (). Alert type Exelixis SEC Alert Exelixis End-of-Day SEC Alert Exelixis Calendar Alert Exelixis News Alert Exelixis Report Alert Email Leave this field blank Shareholder Tools Information Request Print Page RSS
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March Read more about Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March
Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer Read more about Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer
Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026 Read more about Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026
Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer Read more about Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer
Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026 Read more about Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026
Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025 Read more about Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November Read more about Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November
Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 Read more about Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
Exelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development Read more about Exelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September Read more about Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September
